Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3025340 | Seminars in Thoracic and Cardiovascular Surgery | 2012 | 6 Pages |
Abstract
Neoadjuvant chemoradiation is the standard of care for locally advanced esophageal cancer. After completion of chemoradiotherapy, deciding which patients benefit from surgery remains a challenge. For patients who decide on surgery, the optimal timing is unknown. The complexity of these questions requires an individualized approach, taking into account the expertise of the surgeon, the condition of the patient, and the biology of the tumor.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Jae Y. Kim, Wayne L. Hofstetter,